Video

Sikarin Upala from Bassett Medical Center: Using Caffeine to Slow Progression of Hepatitis C and Hepatic Fibrosis

A recent study looked to shed light on the long-researched belief that caffeine decreases the risk of advanced hepatic fibrosis in people with hepatitis C.

A recent study looked to shed light on the long-researched belief that caffeine decreases the risk of advanced hepatic fibrosis in people with hepatitis C.

Sikarin Upala, MD, Bassett Medical Center, spoke about using caffeine to slow the progression of Hepatitis C and Hepatic Fibrosis during DDW 2016 in San Diego.

The research aimed to determine if there was any correlation between caffeine intake and hepatitis c infection or liver fibrosis. In the studies, caffeine beverages were consumed, whether one cup or several cups a day.

“We found those in the group who consumed caffeine reduced the risk of chronic Hepatitis C by 61 percent, compared to the group that did not have caffeine consumption,” Upala said.

The risk was specific to those who had hepatitis c and could then have advanced to liver cirrhosis as a result of that risk, he said. “Caffeine also helped improve the liver function of the caffeine group,” he added.

Upala said the research is significant because caffeine is so widely available in food and drink products. He recommended more studies, including randomized control trials, as his research was general data.

Also on MD Magazine >>> More news from Digestive Disease Week 2016

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.